ArticleThe Journal of clinical investigation2006
Deconstructing endothelial dysfunction: soluble guanylyl cyclase oxidation and the NO resistance syndrome.
Article in The Journal of clinical investigation, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 84 citations in OpenAlex.
- NO-cGMP Signaling in Endothelial Function of the Healthy and Inflamed Dental Pulp.International journal of molecular sciences · 2025Review
- A Phase II study of avenciguat, a novel soluble guanylate cyclase activator, in patients with systemic sclerosis: Study design and rationale of the VITALISScE™ study.Journal of scleroderma and related disorders · 2025Article
- Vascular nitric oxide resistance in type 2 diabetes.Cell death & disease · 2023Review
- Thiol catalyzed formation of NO-ferroheme regulates canonical intravascular NO signaling.Research square · 2023Article
- Dental Pulp Inflammation Initiates the Occurrence of Mast Cells Expressing the αInternational journal of molecular sciences · 2023Article
- Nitric oxide augments signaling for contraction in hypoxic pulmonary arterial smooth muscle-Implications for hypoxic pulmonary hypertension.Frontiers in physiology · 2023Article
- Endogenous Hemoprotein-Dependent Signaling Pathways of Nitric Oxide and Nitrite.Inorganic chemistry · 2021Review
- Soluble Guanylate Cyclase Stimulators and Activators.Handbook of experimental pharmacology · 2021Article
- Ambient air pollution and sickle cell disease-related emergency department visits in Atlanta, GA.Environmental research · 2020Observational
- Review
- Pathophysiology of Sickle Cell Disease.Annual review of pathology · 2019Review
- Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their RegulationPhysiological reviews · 2019Review
- Nitric Oxide-Independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell Disease.American journal of respiratory cell and molecular biology · 2018Article
- Chronic limb-threatening ischemia could benefit from growth hormone therapy for wound healing and limb salvage.Therapeutic advances in cardiovascular disease · 2018Review
- Contemporary Approaches to Modulating the Nitric Oxide-cGMP Pathway in Cardiovascular Disease.Circulation research · 2017Review
- Regulation of sGC via hsp90, Cellular Heme, sGC Agonists, and NO: New Pathways and Clinical Perspectives.Antioxidants & redox signaling · 2017Article
- Article
- Soluble guanylate cyclase as an alternative target for bronchodilator therapy in asthma.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- The sGC stimulator riociguat inhibits platelet function in washed platelets but not in whole blood.British journal of pharmacology · 2015Article
- Chronic Activation of Heme Free Guanylate Cyclase Leads to Renal Protection in Dahl Salt-Sensitive Rats.PloS one · 2015Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this issue of the JCI, Stasch and colleagues suggest that a novel drug, BAY 58-2667, potently activates a pool of oxidized and heme-free soluble guanylyl cyclase (sGC; see the related article beginning on page 2552). The increased vasodilatory potency of BAY 58-2667 the authors found in a number of animal models of endothelial dysfunction and in human blood vessels from patients with diabetes suggests that there exists a subphenotype of endothelial dysfunction characterized by receptor-level NO resistance. Diseases associated with NO resistance would appear to be ideally suited for therapies directed at restoring redox homeostasis, sGC activity, and NO sensitivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.